Abstract:CXCR3 is a CXC chemokine receptor that, together with its three major ligands, CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC), is involved in inflammatory responses, mediated mainly by T cells. In several immune-related diseases, including chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), rheumatoid arthritis, multiple sclerosis, and atherosclerosis, CXCR3 and/or its ligands are found to be overexpressed, potentially indicating a role for this receptor in these diseases. Animal models have confirmed the therapeutic potential of targeting CXCR3 in the treatment of such diseases. Several peptidic, peptidomimetic, and small non-peptidomimetic CXCR3 ligands have been disclosed in the past 10 years. These ligands have served as chemical tools for the investigation of CXCR3 activation, blocking, and signaling, and some of these ligand series have been developed as potential therapeutic agents against inflammation. Computational modeling studies, facilitated by the recent developments in GPCR structural biology, together with mutagenesis and pharmacological studies, have aided in understanding how these ligands interact with CXCR3.This chapter will give an overview on how the combination of these chemical, computational, and pharmacological tools and techniques has increased our understanding of the molecular mechanisms by which small-molecule antagonists and agonists bind to CXCR3 compared to the relatively large chemokines. A detailed overview of CXCR3 ligand structure-activity relationships and structure-function relationships will be presented. This comparative analysis reveals that the full spectrum of antagonist and agonist effects on CXCR3 is now within reach by appropriate scaffolds and chemical modifications. Many of these ligands display behavior deviating from simple competition and do not interact with the chemokine binding site, providing evidence for an allosteric mode of action. Moreover, the computer-assisted molecular modeling of CXCR3 receptor-ligand interactions is discussed in view of GPCR crystal structures and mutagenesis studies of CXCR3 and other chemokine receptors. Improved insights in the interplay between CXCR3-ligand interactions and CXCR3-mediated signaling pathways potentially open up novel therapeutic opportunities in the area of inflammation.

Studying allosteric regulation of chemokines and antagonists using a nanoscale hCCR3 receptor sensor

Molecular Insights into Ligand Recognition and Activation of Chemokine Receptors CCR2 and CCR3

Computational Studies of the Binding Modes of Ccr1 Antagonists

Discovery and Mapping of an Intracellular Antagonist Binding Site at the Chemokine Receptor CCR2

Structural insights into the activation and inhibition of CXC chemokine receptor 3

Milligram Production and Biological Activity Characterization of the Human Chemokine Receptor CCR3

Study On Interaction Of Human Chemokine Receptor Ccr3 And Beta-Arrestin

Exploring an Intracellular Allosteric Site of CC-Chemokine Receptor 4 from 3D Models, Probe Simulations, and Mutagenesis

A fluorescent probe enables the discovery of improved antagonists targeting the intracellular allosteric site of the chemokine receptor CCR7

Regulation of the Oligomeric Status of CCR3 with Binding Ligands Revealed by Single-Molecule Fluorescence Imaging.

Identification of a novel allosteric binding site in the CXCR2 chemokine receptor

3D-Pharmacophere Models for CC Chemokine Receptor 1 Antagonists.

Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5

Profiling CCR3 target pathways for discovering novel antagonists from natural products using label-free cell phenotypic assays

Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies

Unveiling the structural mechanisms of nonpeptide ligand recognition and activation in human chemokine receptor CCR8

Structural insights into the activation of chemokine receptor CXCR2

Study on The Interaction Between Chemokine CCL11-glycosaminoglycan- chemokine Receptor CCR3

Identification and mechanism of G protein-biased ligands for chemokine receptor CCR1

Biophysical characterization of the CXC chemokine receptor 2 ligands

Exploring the CXCR3 Chemokine Receptor with Small-Molecule Antagonists and Agonists